MedTrace Logo

Plasma Exosome RNA to Diagnose Prostate Cancer

NCT06604130 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2025-11-28

No results posted yet for this study

Summary

The aim of the present study is to investigate a RNA combination to diagnose prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Prostate cancer screening decision

The subjects would receive serum PSA test.

Sponsors & Collaborators

  • Shaanxi Provincial People's Hospital

    collaborator OTHER

  • Yan'an University Affiliated Hospital

    collaborator OTHER

  • Weinan Central Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

    collaborator UNKNOWN

  • Affiliated Hospital of Qinghai University

    collaborator OTHER

  • General Hospital of Ningxia Medical University

    collaborator OTHER

  • LanZhou University

    collaborator OTHER

  • Air Force 986 Hospital

    collaborator UNKNOWN

  • Xijing Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604130 on ClinicalTrials.gov